Shilpa Medicare has entered a monetisation phase after significant investments in R&D and manufacturing, spending over Rs. 800 crore on R&D and Rs. 1,200 crore on capex from FY21-FY25. The company reported a 74% increase in formulation revenue and a doubling of biologics revenue in FY26, with consolidated revenue rising nearly 20% to Rs 1,538 crore and EBITDA increasing by 37% to Rs 434 crore. Analysts project continued growth in revenue and EBITDA driven by specialty formulations and biologics, with a forecasted revenue of Rs 1,818 crore in FY27.

Shilpa Medicare announced a strategic partnership with Orion Corporation Finland and received a 'Buy' rating from DAM Capital, which has positively influenced investor sentiment.